[View original text] 

Artificial intelligence-based cervical cancer screening system for cervical cancer prevention in Bolivia - taking the lead in eradication

On 21st of October, AIDOT (CEO Jae-hoon Jeong) announced that On 18th, AIDOT was finally selected for the 2022-2023 KOICA Creative Technology Solution.

The project applies innovative ideas and technologies of start-ups and social venture innovators to Official Development Assistance (ODA) to contribute to finding solutions to difficult development cooperation challenges that were difficult to solve through conventional methods, and to increase the effectiveness of development cooperation projects to be. Through this, AIDOT will be able to use its artificial intelligence-based cervical cancer screening system 'Cerviray' to prevent cervical cancer in South America including Bolivia.

Bolivia has the highest incidence of cervical cancer in South America. The incidence of cervical cancer per 100,000 population is 36.6, which ranks first among female cancers in 

Bolivia.

In Bolivia, cervical cancer cell testing is provided free of charge according to the government health policy, but due to lack of training, the sample misdiagnosis rate is as high as 80%, and it takes 3 to 4 months to receive the results due to the lack of laboratories and pathologists.

AIDOT's global sales and marketing PIC said that “Bolivia lacks medical infrastructure and is geographically disadvantageous, making cell and HPV tests unsuitable, and the existing 

VIA screening method is limited due to the lack of medical staff’s competence or reading doctors". Therefore, Cerviray could be the solution for the situation in Bolivia which assists 

reading and can remotely connect the reading of a metropolitan medical specialist."

“Unlike other products that show results through simple binary classification, Cerviray is a medical device that has obtained medical device certification for artificial intelligence 

software and has been clinically validated,” he said. “It can be most appropriately used for cervical cancer screening in Bolivia. that,” he explained.

Director Yon-jon Jung, who is in charge of this project, said, “The entry into Bolivia through KOICA will be a signal to pioneer the South American market.” It will be reborn as a good 

business that can save people.”

2022.10.21 / Pharm News / Reporter Kwon-gu Lee